Emerging roles of human prostatic Acid phosphatase

• Published in: Biomolecules & therapeutics Vol. 21; no. 1; pp. 10 - 20
• Main Authors: Kong, Hoon Young, Byun, Jonghoe
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society of Applied Pharmacology 2013; 한국응용약물학회
• Subjects: 약학; Biomarker; Prognosis; Diagnosis; Prostate cancer; Immunotherapy; Prostatic acid phosphatase (PAP)
• ISSN: 1976-9148; 2005-4483
• DOI: 10.4062/biomolther.2012.095

Prostate cancer is one of the most prevalent non-skin related cancers. It is the second leading cause of cancer deaths among males in most Western countries. If prostate cancer is diagnosed in its early stages, there is a higher probability that it will be completely cured. Prostatic acid phosphatase (PAP) is a non-specific phosphomonoesterase synthesized in prostate epithelial cells and its level proportionally increases with prostate cancer progression. PAP was the biochemical diagnostic mainstay for prostate cancer until the introduction of prostate-specific antigen (PSA) which improved the detection of early-stage prostate cancer and largely displaced PAP. Recently, however, there is a renewed interest in PAP because of its usefulness in prognosticating intermediate to high-risk prostate cancers and its success in the immunotherapy of prostate cancer. Although PAP is believed to be a key regulator of prostate cell growth, its exact role in normal prostate as well as detailed molecular mechanism of PAP regulation is still unclear. Here, many different aspects of PAP in prostate cancer are revisited and its emerging roles in other environment are discussed.